Screener
Summit Therapeutics SMMT Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| General and administrative | 62,594 | 15,586 |
| Total operating expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 775,458,141 | 738,076,003 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's net income?
- Summit Therapeutics (SMMT) reported net income of -$189.42M in Q1 2026.
- How has Summit Therapeutics's net income changed year-over-year?
- Summit Therapeutics's net income decreased by 201.1% year-over-year, from -$62.91M to -$189.42M.
- What is the long-term trend for Summit Therapeutics's net income?
- Over 4 years (2021 to 2025), Summit Therapeutics's net income has grown at a 86.8% compound annual growth rate (CAGR), from -$88.6M to -$1.08B.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Summit Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude